Carmelo Cuffari is a Board-Certified Pediatric Gastroenterologist who did his pediatric residency at The Children’s Hospital of Eastern Ontario, and fellowship training at Ste. Justine’s Hospital, Montreal, Canada. Professor Cuffari joined the Division of Pediatric Gastroenterology at The Johns Hopkins Hospital in October 1, 1996, and has acquired a special interest in the study of immunosuppressant therapies in inflammatory bowel disease (IBD). During his research Fellowship training, Professor Cuffari developed an HPLC assay that measures azathioprine metabolite levels and applied this technology in the management of patients with IBD. This research developed the concept of a therapeutic window of treatment efficacy and toxicity based on the measurement of erythrocyte 6-thioguanine metabolite levels. His research interests include the study of pharmacogenetic differences in azathioprine metabolism and its effect on patient responsiveness to therapy, and the clinical application of novel intravenous forms of azathioprine therapy in the treatment of IBD. Professor Cuffari runs the immunosuppressant-monitoring laboratory at The Johns Hopkins Hospital.
Biography Updated on 29 August 2012